Peter Attia· MD
like p53 present in half of all cancers but only about 2% of patients develop immune reactions against it K about 90% of pancreatic cancers will have that as a driver mutation
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
like p53 present in half of all cancers but only about 2% of patients develop immune reactions against it K about 90% of pancreatic cancers will have that as a driver mutation
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
well it turns out that some of these antigens that are recognized by the by te- cells are recognizing the proteins that derive from driver mutations that is that caus the cancer in the first place like p53 present in half of all cancers but only about 2% of patients develop immune reactions against it K about 90% of pancreatic cancers will have that as a driver mutation
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.